In this task force, we will focus on drug-induced periocular and ocular surface disorders. Many systemic and topical drugs may cause mild to severe muco-cutaneous surface adverse effects which might lead to periocular inflammation, conjunctival and corneal scarring, blindness and even threaten life. They are most commonly classified as either a toxic reaction or a delayed type hypersensitivity reaction. Systemic antibiotics, anti-viral drugs and anti-convulsant might cause Stevens-Johnson Syndrome or other SCARs. Antihistamines, beta blockers, antipsychotics/antidepressants, isotretinoin, etc. might lead to dry eye disease. Topical antibiotics, antiglaucoma agents, preservatives, contact lens solutions and cosmetics also cause allergic reactions in the eye and/or be toxic to the ocular surface disease. Recent reports showed that patients using biological treatments for oncological diseases (Epidermal growth factor) and atopic dermatitis (dupilumumab) should be followed for possible ocular surface side effects. Epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used for malignancies of epithelial origin. They are currently approved to treat non-small-cell lung cancer, squamous-cell carcinoma of the head and neck, colorectal cancer, pancreatic cancer, and breast cancer. They are associated with conjunctivitis, meibomitis, dry eye, periocular skin changes and trichomegaly. Dupilumab is the first biologic registered for the treatment of moderate-to-severe atopic dermatitis (AD). There are some ocular complications related to dupilumab such as periocular dermatitis, blepharitis, bilateral conjunctivitis, cicatricial ectropion, Herpes Simplex Virus (HSV) reactivation. These disorders are generally managed by dermatologists, internal specialists, pediatricians, allergologists and ophthalmologists there is a need for a position paper which will address the main clinical findings, diagnostic and treatment approaches with the newest literature.

Chair: Andrea Leonardi
Secretary: Banu Bozkurt